Bluefish’ owners continue to invest in the company

Swedish specialty pharma company Bluefish pulls in SEK 20 million in new capital in order to continue its expansion in Europe. The company is instilling strong confidence in its owners as it constantly increases its portfolio of generic pharmaceuticals with enormous sales potential in Europe. In addition, the owner Quesada has redeemed an earlier share option worth SEK 5 million.

Investors in the recent new share issue include Catella Funds, who is increasing its ownership, SEB Generic Pharma Fund, Mangold Fonder, and CEO Karl Karlsson.

“Our owners are demonstrating their strong support, and we are happy that they have chosen to continue investing in Bluefish. The market for generic pharmaceuticals is showing dramatic growth throughout Europe. We are well-positioned to take advantage of this growth,” says CEO Karl Karlsson.

Bluefish is aiming to publicly list the company within the next year.
The company currently has 14 pharmaceuticals that are approved or under registration in the EU. Bluefish pharmaceuticals are manufactured in India where Bluefish has a wholly-owned subsidiary. One of the company’s products is omeprazol, one of the biggest selling drugs in Europe. In Sweden, sales of omeprazol surpassed SEK 300 million in 2006.

Saxon & Partners have been financial advisors to the company during the latest share issue.
For more information, please contact: Karl Karlsson, CEO, tel +46 8 679 50 70

Bluefish Pharmaceuticals AB is a Swedish specialty pharma company that buys or licenses the rights to manufacture pharmaceuticals, mainly generic products. Low prices are maintained through efficient production and distribution. Bluefish has a wholly-owned subsidiary in Chennai, India focused on product development and production. The company is owned by its founder Karl Karlsson, and a number of funds and private investors.